Australian Clinical Labs Limited (ASX: ACL)
Australia
· Delayed Price · Currency is AUD 3.470
+0.050 (1.46%)
Nov 21, 2024, 4:10 PM AEST
Australian Clinical Labs Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2017 |
| Revenue | 696.37 | 696.37 | 697.07 | 995.6 | 646.7 | 490.57 | Upgrade
|
| Revenue Growth (YoY) | -0.10% | -0.10% | -29.99% | 53.95% | 31.83% | 9.39% | Upgrade
|
| Cost of Revenue | 442.37 | 442.37 | 445.45 | 546.98 | 390.18 | 349.55 | Upgrade
|
| Gross Profit | 254 | 254 | 251.62 | 448.62 | 256.53 | 141.02 | Upgrade
|
| Other Operating Expenses | 63.02 | 63.02 | 63.65 | 68.54 | 40.47 | 44.65 | Upgrade
|
| Operating Expenses | 191.45 | 191.45 | 186.4 | 174.64 | 128.53 | 122.56 | Upgrade
|
| Operating Income | 62.55 | 62.55 | 65.22 | 273.98 | 128 | 18.47 | Upgrade
|
| Interest Expense | -17.04 | -17.04 | -13.47 | -11.75 | -15.13 | -16.57 | Upgrade
|
| Interest & Investment Income | 0.5 | 0.5 | 0.18 | 0.05 | 0.08 | 0.04 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.4 | - | -18.46 | - | Upgrade
|
| EBT Excluding Unusual Items | 46.01 | 46.01 | 51.53 | 262.28 | 94.49 | 1.88 | Upgrade
|
| Merger & Restructuring Charges | -6.17 | -6.17 | -2.63 | -8.94 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.05 | Upgrade
|
| Other Unusual Items | -4.65 | -4.65 | -3.28 | - | -7.83 | 28.9 | Upgrade
|
| Pretax Income | 36.37 | 36.37 | 48.31 | 254.9 | 86.65 | 30.83 | Upgrade
|
| Income Tax Expense | 12.12 | 12.12 | 12.27 | 76.5 | 26.26 | -10.43 | Upgrade
|
| Earnings From Continuing Operations | 24.24 | 24.24 | 36.04 | 178.4 | 60.39 | 41.26 | Upgrade
|
| Minority Interest in Earnings | -0.31 | -0.31 | -0.14 | -0.16 | -0.02 | - | Upgrade
|
| Net Income | 23.93 | 23.93 | 35.9 | 178.24 | 60.37 | 41.26 | Upgrade
|
| Net Income to Common | 23.93 | 23.93 | 35.9 | 178.24 | 60.37 | 41.26 | Upgrade
|
| Net Income Growth | -33.33% | -33.33% | -79.86% | 195.24% | 46.34% | - | Upgrade
|
| Shares Outstanding (Basic) | 199 | 199 | 201 | 201 | 152 | 145 | Upgrade
|
| Shares Outstanding (Diluted) | 199 | 199 | 201 | 201 | 152 | 145 | Upgrade
|
| Shares Change (YoY) | -0.82% | -0.82% | -0.18% | 32.47% | 4.65% | - | Upgrade
|
| EPS (Basic) | 0.12 | 0.12 | 0.18 | 0.89 | 0.40 | 0.28 | Upgrade
|
| EPS (Diluted) | 0.12 | 0.12 | 0.18 | 0.88 | 0.40 | 0.28 | Upgrade
|
| EPS Growth | -32.77% | -32.77% | -79.82% | 122.88% | 39.83% | - | Upgrade
|
| Free Cash Flow | 153.09 | 153.09 | 136.75 | 262.84 | 144.36 | 92.36 | Upgrade
|
| Free Cash Flow Per Share | 0.77 | 0.77 | 0.68 | 1.30 | 0.95 | 0.64 | Upgrade
|
| Dividend Per Share | 0.120 | 0.120 | 0.140 | 0.530 | 0.142 | 0.144 | Upgrade
|
| Dividend Growth | -14.29% | -14.29% | -73.58% | 271.93% | -1.38% | - | Upgrade
|
| Gross Margin | 36.47% | 36.47% | 36.10% | 45.06% | 39.67% | 28.75% | Upgrade
|
| Operating Margin | 8.98% | 8.98% | 9.36% | 27.52% | 19.79% | 3.76% | Upgrade
|
| Profit Margin | 3.44% | 3.44% | 5.15% | 17.90% | 9.34% | 8.41% | Upgrade
|
| Free Cash Flow Margin | 21.98% | 21.98% | 19.62% | 26.40% | 22.32% | 18.83% | Upgrade
|
| EBITDA | 76.31 | 76.31 | 79.71 | 286.36 | 138.19 | 29.78 | Upgrade
|
| EBITDA Margin | 10.96% | 10.96% | 11.43% | 28.76% | 21.37% | 6.07% | Upgrade
|
| D&A For EBITDA | 13.76 | 13.76 | 14.49 | 12.37 | 10.19 | 11.31 | Upgrade
|
| EBIT | 62.55 | 62.55 | 65.22 | 273.98 | 128 | 18.47 | Upgrade
|
| EBIT Margin | 8.98% | 8.98% | 9.36% | 27.52% | 19.79% | 3.76% | Upgrade
|
| Effective Tax Rate | 33.33% | 33.33% | 25.39% | 30.01% | 30.31% | - | Upgrade
|
| Revenue as Reported | 697.54 | 697.54 | 704.76 | 997.17 | 644.67 | 519.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.